Biofil Chemicals & Pharmaceuticals Ltd.
Snapshot View

View in App

Prices View details

56.55 -1.25 ▼-2.2%

25 May 2022, 04:01:00 PM
Volume: 4,444

Overview View Details

Sector Healthcare Compare with Sector peers
Industry Pharmaceuticals & Drugs Compare with Industry peers
Website http://www.biofilgroup.net
Market Cap 92.27 Cr.
Enterprise Value(EV) 92.33 Cr. 2021-09
Financial Indicators
Earnings per share (EPS) 0.19 Trailing Twelve Months Ending 2021-12
Price-Earning Ratio (PE) 294.80 Trailing Twelve Months Ending 2021-12
Industry PE 28.07 Trailing Twelve Months Ending 2021-12
Book Value / Share 10.36 Trailing Twelve Months Ending 2021-12
Price to Book Value 5.47 Calculated using Price: 56.70
Dividend Yield 0.00 Period Ending 2021-03
No. of Shares Subscribed 1.63 Cr. 16,273,800 Shares
FaceValue 10
Company Profile

Biofil Chemicals & Pharmaceuticals established in 1985, is part of Cyano Group of Industries. The company is into manufacturing of drugs in area of anti-bacterial, analgesics/antipyretics, anti-malarial, anti-psychotics, anti asthmatic/bronchodilators, diuretics, tranquilizer/hypnotics, anti inflammatory, analgesic/antipyretics, anti inflammatory steroids and eye/ear drops

Its plant is located at Plot No. 8, Sector-IV Kheda Industrial Estate, Pithampur, Dhar District, Madhya Pradesh. The facility has received GMP certificate from Licensing Authority, Food & Drugs Administration, Department of Health and Government of Madhya Pradesh, India.

The manufacturing unit exports around 30 to 40% of their formulation directly or through merchant export to countries in own or neutral labels.

The shares of companies are listed on Bombay Stock Exchange.

Company exports its products to countries namely Kenya, Uganda, Tanzania, Nigeria, U.A.E, Rwanda, Monrovia, Republic of Yemen and Mauritius.

Delivery View Details

Delivered Qty
Traded Qty

Performance View Details

1 Day
-2.16%
1 Week
-3.42%
1 Month
-14.71%
3 Month
-8.50%
6 Month
-6.84%
1 Year
-20.74%
2 Year
+309.19%
5 Year
+403.11%
10 Year
+1286.03%

Ratios View Details

9 years 2013-03 2014-03 2015-03 2016-03 2017-03 2018-03 2019-03 2020-03 2021-03
Return on Equity (%) 16.49 13.53 13.47 13.28 18.09 3.64 3.60 8.46 8.01
Return on Capital Employed (%) 14.53 12.09 12.97 14.04 21.86 5.13 5.06 10.12 12.18
Return on Assets (%) 3.93 3.68 4.14 4.13 7.81 2.05 1.99 3.63 3.28

Balance Sheet View Details

Particulars 10 years 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2021-09* Rs. Cr.
Shh. Funds 7 8 8 11 13 13 14 15 16 17
Non Curr. Liab. 0 0
Curr. Liab. 6 7 5 13 9 11 11 27 17 21
Minority Int.
Equity & Liab. 13 15 14 24 22 24 24 42 33 38
Non Curr. Assets 9 9 9 9 9 9 10 10 10 10
Curr. Assets 4 5 5 15 13 15 14 32 23 28
Misc. Exp. not W/O
Total Assets 13 15 14 24 22 24 24 42 33 38

Profit Loss View Details

Particulars 10 years 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2021-12 Rs. Cr. TTM
Net Sales 6 7 6 13 13 12 23 30 36 35
Other Income 0 0 0 1 0 0 0 0 1 0
Total Income 6 7 6 14 14 12 23 30 37 35
Total Expenditure -5 -6 -5 -12 -11 -11 -22 -28 -34 -33
PBIDT 1 1 1 1 3 1 1 2 2 2
Interest 0 0 0 0 0 0 0 0 0 0
Depreciation 0 0 0 0 0 0 0 0 0 -1
Taxation 0 0 0 0 -1 0 0 0 -1 -1
Exceptional Items
PAT 1 1 1 1 2 0 0 1 1 0
Adjusted EPS 0 0 0 0 1 0 0 1 1 0

Cash Flow View Details

Particulars 10 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr.
Cash Fr. Operatn. 0 0 0 0 0 1 0 1 1 1
Cash Fr. Inv. -1 0 0 0 0 0 0 -1 0 0
Cash Fr. Finan. 1 0 0 0 0 0 0 0 -1 -1
Net Change 0 0 0 0 0 0 0 0 0 0
Cash & Cash Eqvt 0 0 0 0 0 0 0 0 0 0

Shareholding Pattern View Details

9 Qtrs 2020-03 (%) 2020-06 (%) 2020-09 (%) 2020-12 (%) 2021-03 (%) 2021-06 (%) 2021-09 (%) 2021-12 (%) 2022-03 (%)
Promoter 46.82 46.82 46.82 46.82 46.82 46.82 46.82 46.82 46.82
Public 53.18 53.18 53.18 53.18 53.18 53.18 53.18 53.18 53.18
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Announcements View Details

Sat, 21 May 2022
Board Meeting Intimation for Filing Of Intimation For Meeting Of Board Of Directors (Serial No. 01/2022-23) Of The Company Scheduled To Be Held On Monday 30Th May 2022 As Per Regulation 29 Of SEBI (Listing Obligations & Disclosure Requirements) Regulations 2015.
BIOFIL CHEMICALS & PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/05/2022 inter alia to consider and approve 1. Audited Financial Results of the company for the Quarter as well as Year ended on 31st March 2022 along with Auditors Report thereon.2. Any other routine businesses with the permission of the chair.Further in continuation to earlier disclosure dated 29th March 2022 pursuant to Companys Code of Conduct to regulate monitor and report trading in Companys Securities by Insider framed under SEBI (Prohibition of Insider Trading) Regulations 2015 as amended Trading window for dealing in the securities of the Company shall open after 48 hours of declaration of Audited Financial Results for all designated persons their immediate relatives and all connected persons covered under the aforesaid code.
Mon, 25 Apr 2022
Submission Of Certificate Under Regulation 40(9) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 For The Financial Year Ended On 31St March 2022
In Compliance with Regulation 40(9) of SEBI Listing Obligations and Disclosure Requirements Regulations 2015 we are submitting herewith Certificate from Practicing Company Secretary for the financial year ended on 31st March 2022.Please find the same in order and oblige Thanking You Yours FaithfullyFor Biofil Chemicals & Pharmaceuticals Ltd. CS Shikha Khilwani Company Secretary &Compliance Officer
Thu, 21 Apr 2022
Format of Initial Disclosure to be made by an entity identified as a Large Corporate
Format of Initial Disclosure to be made by an entity identified as a Large Corporate.

Sr. No. Particulars Details
1Name of CompayBIOFIL CHEMICALS & PHARMACEUTICALS LTD.
2CINL24233MP1985PLC002709
3 Outstanding borrowing of company as on 31st March / 31st December as applicable (in Rs cr) 0.00
4Highest Credit Rating during the previous FY NA
4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)Not Applicable
5Name of Stock Exchange# in which the fine shall be paid in case of shortfall in the required borrowing under the frameworkBSE


We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26 2018. No



Name of the Company Secretary: SHIKHA KHILWANI
Designation: COMPANY SECRETARY COMPLIANCE OFFICER
EmailId: bcplcompliance@gmail.com
Name of the Chief Financial Officer: JITENDRA KUMAR SAHU
Designation: CHIEF FINANCIAL OFFICER
EmailId: biofilchemicals@yahoo.com

Date: 21/04/2022

Note: In terms para of 3.2(ii) of the circular beginning F.Y 2022 in the event of shortfall in the mandatory borrowing through debt securities a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore an entity identified as LC shall provide in its initial disclosure for a financial year the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets.

Technical Scans View Details

Wed, 25 May 2022
High Delivery Percentage High Delivery Percentage
Higher Delivery Quantity Higher Delivery Quantity
Higher Delivery Quantity and Percentage Higher Delivery Quantity and Percentage
Opening at High Opening at High
Closing Below Previous Low Closing Below Previous Low

Related Stocks View Details

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 218,615.41 911.15 +0.1%
Divi's Laboratories Ltd. 93,410.43 3,518.70 -3.9%
Cipla Ltd. 78,373.92 971.35 +0.1%
Dr. Reddy's Laboratories Ltd. 71,774.48 4,312.70 -0.9%
Apollo Hospitals Enterprise Ltd. 50,694.88 3,525.75 -2.9%
Gland Pharma Ltd. 45,552.31 2,767.85 -3.6%
Torrent Pharmaceuticals Ltd. 44,253.16 2,615.30 +0.9%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-12 33.92 911.15 +0.1%
Divi's Laboratories Ltd. Consolidated 2022-03 31.55 3,518.70 -3.9%
Cipla Ltd. Consolidated 2022-03 31.14 971.35 +0.1%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 32.89 4,312.70 -0.9%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-12 44.73 3,525.75 -2.9%
Gland Pharma Ltd. Consolidated 2022-03 37.59 2,767.85 -3.6%
Torrent Pharmaceuticals Ltd. Consolidated 2021-12 36.30 2,615.30 +0.9%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-12 4.23 911.15 +0.1%
Divi's Laboratories Ltd. Consolidated 2022-03 7.96 3,518.70 -3.9%
Cipla Ltd. Consolidated 2022-03 3.76 971.35 +0.1%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 3.74 4,312.70 -0.9%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-12 9.16 3,525.75 -2.9%
Gland Pharma Ltd. Consolidated 2022-03 6.36 2,767.85 -3.6%
Torrent Pharmaceuticals Ltd. Consolidated 2021-12 6.84 2,615.30 +0.9%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 0.08 911.15 +0.1%
Divi's Laboratories Ltd. Consolidated 2021-03 0.00 3,518.70 -3.9%
Cipla Ltd. Consolidated 2021-03 0.10 971.35 +0.1%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 0.17 4,312.70 -0.9%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 0.62 3,525.75 -2.9%
Gland Pharma Ltd. Consolidated 2021-03 0.00 2,767.85 -3.6%
Torrent Pharmaceuticals Ltd. Consolidated 2021-03 0.84 2,615.30 +0.9%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 4.98 911.15 +0.1%
Divi's Laboratories Ltd. Consolidated 2021-03 23.90 3,518.70 -3.9%
Cipla Ltd. Consolidated 2021-03 14.13 971.35 +0.1%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 11.53 4,312.70 -0.9%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 3.44 3,525.75 -2.9%
Gland Pharma Ltd. Consolidated 2021-03 20.97 2,767.85 -3.6%
Torrent Pharmaceuticals Ltd. Consolidated 2021-03 23.49 2,615.30 +0.9%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 4.98 911.15 +0.1%
Divi's Laboratories Ltd. Consolidated 2021-03 23.90 3,518.70 -3.9%
Cipla Ltd. Consolidated 2021-03 14.13 971.35 +0.1%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 11.53 4,312.70 -0.9%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 3.44 3,525.75 -2.9%
Gland Pharma Ltd. Consolidated 2021-03 20.97 2,767.85 -3.6%
Torrent Pharmaceuticals Ltd. Consolidated 2021-03 23.49 2,615.30 +0.9%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 33,498.14 911.15 +0.1%
Divi's Laboratories Ltd. Consolidated 2021-03 6,969.40 3,518.70 -3.9%
Cipla Ltd. Consolidated 2021-03 19,159.59 971.35 +0.1%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 19,047.50 4,312.70 -0.9%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 10,560.00 3,525.75 -2.9%
Gland Pharma Ltd. Consolidated 2021-03 3,462.88 2,767.85 -3.6%
Torrent Pharmaceuticals Ltd. Consolidated 2021-03 8,004.83 2,615.30 +0.9%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 2,284.68 911.15 +0.1%
Divi's Laboratories Ltd. Consolidated 2021-03 1,984.29 3,518.70 -3.9%
Cipla Ltd. Consolidated 2021-03 2,401.30 971.35 +0.1%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 1,903.60 4,312.70 -0.9%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 136.00 3,525.75 -2.9%
Gland Pharma Ltd. Consolidated 2021-03 996.96 2,767.85 -3.6%
Torrent Pharmaceuticals Ltd. Consolidated 2021-03 1,251.88 2,615.30 +0.9%